Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 2904 of 5804
-
Experimental diabetes drug trial halted early
Disease control TerminatedThe study is a prospective, randomized, 52-week double-blind, placebo-controlled, multicenter trial in subjects with Type 1 diabetes (T1D) followed by a 2-year safety follow-up.
Phase: PHASE2 • Sponsor: Tolerion, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New vaccine aims to train immune system to fight neuroendocrine tumors
Disease control CompletedThis phase I trial studies the side effects of survivin long peptide vaccine and how it works with the immune system in treating patients with neuroendocrine tumors that have spread to other parts of the body (metastatic). Tumor cells make proteins that are not usually produced b…
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Can an antioxidant boost light therapy for vitiligo?
Symptom relief CompletedThe role of the oxidative stress in vitiligo is supported by many studies but robust data are lacking concerning their interest as therapeutic agents. The objective of the study is to compare the association of GLISODIN (a gastro-protected superoxide dismutase) and Nb-UVB to Nb-U…
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
New hope for rare tumors: drug may slow cancer growth
Disease control OngoingThe objectives of this study are: * To assess the efficacy of lanreotide given every 4 weeks in participants with advanced or metastatic paraganglioma/ pheochromocytoma. * To assess the toxicity and safety of lanreotide in participants with advanced or metastatic paraganglioma/ …
Phase: PHASE2 • Sponsor: Antonio Fojo • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Brain activity clues may predict waking up after stroke
Knowledge-focused Recruiting nowThe objectives of the RECONFIG clinical study are to : 1. To identify the time to the first diagnosis of cognitive motor dissociation (CMD) in intracerebral hemorrhage (ICH) patients and to investigate whether these patients will clinically follow commands earlier after the hemo…
Sponsor: Columbia University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Parent coaching boosts language skills in toddlers with hearing loss
Symptom relief CompletedImproving spoken language outcomes for children with hearing loss has important public health implications. This is a randomized clinical trial of 96 children with hearing loss that examines the effects of a parent-implemented early communication intervention on prelinguistic and…
Phase: PHASE2 • Sponsor: Northwestern University • Aim: Symptom relief
Last updated Jun 27, 2026 07:54 UTC
-
Spinal fluid test may predict shunt success in hydrocephalus patients
Knowledge-focused Recruiting nowIn all published series of adult chronic hydrocephalus, there is a percentage between twenty and twenty-five percent of patients who present poor results after implantation of a cerebrospinal fluid shunt,1-11 usually ventriculoperitoneal. The lumboperitoneal shunt is also used bu…
Sponsor: University of Valencia • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
New study aims to uncover hidden cancer clues in autoimmune disease
Knowledge-focused OngoingThe project is about dermatomyositis (DM), an autoimmune disease characterized by inflammation in the skeletal muscles and skin. Patients with DM have an increased risk of cancer, with a cancer incidence between 5.5% and 42%. Cancers in these patients are one of the leading cause…
Sponsor: Azienda USL Reggio Emilia - IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Autism gene hunt: blood test may reveal hidden causes
Diagnosis CompletedEvaluation of the diagnostic performance of exome sequencing in a prospective series of patients with autism spectrum disorders (ASD).
Phase: NA • Sponsor: University Hospital, Rouen • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC
-
New drug combo shows promise in early cancer trial
Disease control CompletedThe primary objective of this trial is: Part I * To determine Maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of BI 836880 monotherapy Part II * To determine MTD and/or RP2D of the combination therapy of BI 836880 and BI 754091 The secondary objectives are:…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Engineered virus takes on Hard-to-Treat melanoma
Disease control TerminatedThis phase I trial studies the side effects and best dose of a modified virus called VSV-IFNbetaTYRP1 in treating patients with stage III-IV melanoma. The vesicular stomatitis virus (VSV) has been altered to include two extra genes: human interferon beta (hIFNbeta), which may pro…
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Can a short therapy ease depression in advanced cancer?
Symptom relief CompletedThis feasibility study examined the cultural adaptation and implementation of Managing Cancer and Living Meaningfully (CALM) therapy for advanced cancer patients in Korea. CALM is a brief manualized individual psychotherapy designed to address psychological distress and existenti…
Phase: NA • Sponsor: Kyungpook National University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
New drug combo targets Hard-to-Treat breast cancer
Disease control OngoingThe purpose of this study is to test the safety and preliminary efficacy of olaparib and vorinostat when used together in participants with relapsed/refractory and or metastatic breast cancer.
Phase: PHASE1 • Sponsor: The Methodist Hospital Research Institute • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New PET tracer aims to spot prostate cancer more clearly
Diagnosis CompletedA Phase 1, Open-label Study to Assess Safety, Biodistribution, and Internal Radiation Dosimetry of rhPSMA-7.3 (18F) Injection in Healthy Volunteers, and to Assess Safety and Investigate the Imaging Characteristics in Subjects With Prostate Cancer.
Phase: PHASE1 • Sponsor: Blue Earth Diagnostics • Aim: Diagnosis
Last updated Jun 27, 2026 09:04 UTC
-
New study aims to personalize throat cancer treatment using genetic tests and MRI
Knowledge-focused OngoingThis prospective interventional study evaluates the predictive value of tumor mutational burden, liquid biopsy biomarkers (including circulating tumor DNA), angiogenic factors, and dynamic contrast-enhanced magnetic resonance (MR) perfusion imaging in patients with HPV-negative o…
Phase: NA • Sponsor: Institute of Oncology Ljubljana • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC
-
AI analyzes heart scans to predict heart attacks
Knowledge-focused OngoingThe goal of this observational study is to learn whether combining stress echocardiography (stress echo) results with routine clinical information can better predict important heart outcomes in adults (18+) with chest pain who were assessed for suspected coronary artery disease. …
Sponsor: Milton Keynes University Hospital NHS Foundation Trust • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
Can an iPad app boost brain power after tumor treatment?
Symptom relief Recruiting nowPatients with glial brain tumors have increasingly improved outcomes, with median survival of 5-15 years. However, the treatments, including surgery, radiation, and chemotherapy, often lead to impaired attention, working memory, and other cognitive functions. These cognitive defi…
Phase: NA • Sponsor: University of California, San Francisco • Aim: Symptom relief
Last updated Jul 16, 2026 00:00 UTC
-
New drug shows promise for fatty liver – but early days
Disease control CompletedDouble-blind, randomized, placebo-controlled study to explore the efficacy and safety of elobixibat compared to placebo in adults with NAFLD (nonalcoholic fatty liver disease) or NASH (nonalcoholic steatohepatitis)
Phase: PHASE2 • Sponsor: Albireo • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Fewer biopsy cores may be safer and just as accurate for prostate cancer detection
Diagnosis TerminatedThis is a multicentre, paired-cohort, prospective, controlled study. The patient with a suspicion of PCa and a concomitant positive mpMRI (defined as presence of one lesion PI-RADS ≥ 3) will receive a MRI-TBx (4 target cores). During the same session, subsequently to MRI-TBx, pat…
Phase: NA • Sponsor: IRCCS San Raffaele • Aim: Diagnosis
Last updated Jun 27, 2026 13:06 UTC
-
New hope for MDS patients? study tests MBG453 combo but ends early
Disease control TerminatedThis Phase II was a multicenter, randomized, two-arm parallel-group, double-blind, placebo-controlled study of MBG453 or placebo added to hypomethylating agents (azacitidine or decitabine) in adult subjects with IPSS-R intermediate, high or very high risk myelodysplastic syndrome…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC